Omega Fund VI, L.P. 4
4 · SPRUCE BIOSCIENCES, INC. · Filed Oct 16, 2020
Insider Transaction Report
Form 4
Omega Fund VI, L.P.
Other
Transactions
- Purchase
Common Stock
2020-10-14$15.00/sh+250,000$3,750,000→ 2,161,022 total - Conversion
Series B Preferred Stock
2020-10-14−12,500,000→ 0 total→ Common Stock (1,911,022 underlying) - Conversion
Common Stock
2020-10-14+1,911,022→ 1,911,022 total
Footnotes (3)
- [F1]Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date.
- [F2]The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Ms. Dina Chaya Moghrabi, a Director of the Issuer, is an advisor at Omega Fund Management, LLC, an entity affiliated with Omega VI. Each of such individuals, together with Omega VI GP and Omega VI GP Manager and Ms. Moghrabi, disclaims beneficial ownership of the shares held by Omega VI.
- [F3]The shares were purchased in the Issuer's initial public offering.